Brief: Madrigal Receives European Commission Approval for Rezdiffra For Treatment of MASH With Moderate To Advanced Liver Fibrosis
19/08/2025 21:10
Aug 19 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O: MADRIGAL RECEIVES EUROPEAN COMMISSION APPROVAL FOR REZDIFFRA™ (RESMETIROM) FOR TREATMENT OF MASH WITH MODERATE TO ADVANCED LIVER FIBROSIS MADRIGAL PHARMACEUTICALS INC - PLANNING FOR ITS FIRST EUROPEAN LAUNCH IN GERMANY IN Q4 OF 2025 Source text: ID:nGNX5H6zQF Further company coverage: MDGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Madrigal Pharmaceuticals
See all newsBrief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Madrigal Pharmaceuticals Q2 revenue rises 71% on Rezdiffra demand
U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)